GR3031645T3 - Compositions comprising methanediphosphonic acids and ion-exchangers. - Google Patents

Compositions comprising methanediphosphonic acids and ion-exchangers.

Info

Publication number
GR3031645T3
GR3031645T3 GR990402734T GR990402734T GR3031645T3 GR 3031645 T3 GR3031645 T3 GR 3031645T3 GR 990402734 T GR990402734 T GR 990402734T GR 990402734 T GR990402734 T GR 990402734T GR 3031645 T3 GR3031645 T3 GR 3031645T3
Authority
GR
Greece
Prior art keywords
disodium
exchangers
ion
compositions
administration form
Prior art date
Application number
GR990402734T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3031645T3 publication Critical patent/GR3031645T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Sludge (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GR990402734T 1992-04-15 1999-10-27 Compositions comprising methanediphosphonic acids and ion-exchangers. GR3031645T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH124792 1992-04-15

Publications (1)

Publication Number Publication Date
GR3031645T3 true GR3031645T3 (en) 2000-02-29

Family

ID=4205927

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402734T GR3031645T3 (en) 1992-04-15 1999-10-27 Compositions comprising methanediphosphonic acids and ion-exchangers.

Country Status (20)

Country Link
US (1) US5344825A (OSRAM)
EP (1) EP0566535B1 (OSRAM)
JP (1) JP3970941B2 (OSRAM)
KR (1) KR100307786B1 (OSRAM)
AT (1) ATE183096T1 (OSRAM)
AU (1) AU665814B2 (OSRAM)
CA (1) CA2093946C (OSRAM)
DE (1) DE59309727D1 (OSRAM)
DK (1) DK0566535T3 (OSRAM)
ES (1) ES2137241T3 (OSRAM)
FI (1) FI110920B (OSRAM)
GR (1) GR3031645T3 (OSRAM)
HU (1) HU219022B (OSRAM)
IL (1) IL105382A (OSRAM)
MX (1) MX9302151A (OSRAM)
NO (1) NO306978B1 (OSRAM)
NZ (1) NZ247398A (OSRAM)
PH (1) PH30733A (OSRAM)
TW (1) TW237386B (OSRAM)
ZA (1) ZA932613B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
ATE277606T1 (de) * 1997-06-11 2004-10-15 Procter & Gamble Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
MXPA03006565A (es) * 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
JP4142356B2 (ja) 2001-07-05 2008-09-03 オイクロ ヨーロピアン コントラクト リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Pp2cの基質
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
SK2532004A3 (en) * 2001-12-21 2004-11-03 Procter & Gamble Method for the treatment of bone disorders
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
KR100694550B1 (ko) * 2002-12-20 2007-03-13 에프. 호프만-라 로슈 아게 고용량의 이반드로네이트 제형물
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
JP4896480B2 (ja) * 2004-10-01 2012-03-14 第一三共ヘルスケア株式会社 陰イオン交換樹脂の粒子状組成物
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
JP2020536123A (ja) * 2017-10-02 2020-12-10 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム クロファジミンの吸入可能な組成物およびその使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
JPS57177012A (en) * 1981-04-23 1982-10-30 Sumitomo Chem Co Ltd Preparation of chelate resin
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
ES2038693T3 (es) * 1986-11-21 1993-08-01 Ciba-Geigy Ag Nuevos acidos aminometanodifosfonicos substituidos.
US5057505A (en) * 1986-11-21 1991-10-15 Ciba-Geigy Corporation Substituted aminomethanediphosphonic acids and use in medicaments
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate

Also Published As

Publication number Publication date
EP0566535A1 (de) 1993-10-20
NZ247398A (en) 1995-07-26
DE59309727D1 (de) 1999-09-16
HUT63766A (en) 1993-10-28
DK0566535T3 (da) 2000-03-06
HU219022B (hu) 2001-04-28
AU665814B2 (en) 1996-01-18
FI931633A0 (fi) 1993-04-08
JPH069408A (ja) 1994-01-18
CA2093946A1 (en) 1993-10-16
EP0566535B1 (de) 1999-08-11
IL105382A (en) 1998-06-15
IL105382A0 (en) 1993-08-18
FI110920B (fi) 2003-04-30
AU3696193A (en) 1993-10-21
HU9301088D0 (en) 1993-06-28
US5344825A (en) 1994-09-06
NO931367L (no) 1993-10-18
PH30733A (en) 1997-10-17
CA2093946C (en) 2005-07-05
FI931633L (fi) 1993-10-16
MX9302151A (es) 1993-10-01
KR100307786B1 (ko) 2001-11-30
ES2137241T3 (es) 1999-12-16
JP3970941B2 (ja) 2007-09-05
ZA932613B (en) 1993-10-26
KR940005268A (ko) 1994-03-21
NO931367D0 (no) 1993-04-14
NO306978B1 (no) 2000-01-24
ATE183096T1 (de) 1999-08-15
TW237386B (OSRAM) 1995-01-01

Similar Documents

Publication Publication Date Title
GR3031645T3 (en) Compositions comprising methanediphosphonic acids and ion-exchangers.
IL89868A (en) Pharmaceutical compositions for oral administration, based on diphosphonic acid derivatives
EP0202819A3 (en) A delivery system for an active ingredient and a process for preparation thereof
AU7738181A (en) A granular delayed-release medicinal formulation
IL67763A0 (en) Diphosphonic acid derivatives,process for their preparation and pharmaceutical preparations containing them
HK27691A (en) Pharmaceutical compositions
CA2039053A1 (en) Material for adsorbing pyrogen
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
AU563762B2 (en) S-adenosyl-l-methionine salts preparation
ZA881681B (en) Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
AU1888488A (en) Substituted benzimidazoles, a process for the preparation thereof, pharmaceutical formulations containing them, and theuse thereof
PH18051A (en) 3,4-bis-substituted 1,2,5-oxdiazole 2-oxides,a process for their preparation,and pharmaceutical formulations containing them
DE3378315D1 (en) Amino alkylsulphonic derivatives, a process for their preparation and pharmaceutical compositions containing said derivatives
AU1039097A (en) A solution for oral administration containing ici 182,780
IL90219A0 (en) Hydrazinocarbonyloxylabdanes,a process for their preparation and pharmaceutical compositions containing them
AU1283188A (en) Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable nondigestible anion exchange resin
IL74032A (en) Alpha-methyl-6-phenoxy-2-picolyl cyclopropanecarboxylates,process for their preparation and insecticidal,miticidal and acaricidal compositions containing them
IL87678A (en) N-methylene-2,3 -cycloalkylene- (and 2,3-heteroalkylene) -4-quinolinamines, a process for their preparation and pharmaceutical compositions containing them
AU4239889A (en) Process for the preparation of a powdered extract of valerian roots
AU3109589A (en) Indole compounds, a process for their preparation and pharmaceutical compositions containing these compounds
IL91315A0 (en) 2,3,4,5-tetrahydro-1-benzoxepins,a process for the preparation thereof and pharmaceutical compositions based on these compounds
IL92566A0 (en) Anion exchange methacrylate copolymers,processes for their preparation and pharmaceutical compositions containing them
ZA875173B (en) 1,2,3,3a,8,8a,-hexahydro-3a,8(and 1,3a,8)-di(and tri)methyl-pyrrolo(2,3-b)indoles,a process for their preparation and their use as medicaments
GB8826407D0 (en) Pharmaceutical ion exchange resin composition
IL95419A0 (en) Bisphosphonates,a process for preparing them and pharmaceutical compositions containing them